Versio Titl Titl Pro Ide Dat Pro Res Ob Co Ma Ma Ho Th No use or on 3.0 (22 Apr 2 e Page le otocol Versio entifier te of Last Ve otocol search Ques jectives untry(-ies)o in Author rketing Auth lder(s) his study w Paritaprevir/ P15-743 Pro disclose outsid 015) – country v on ersion of stion and of Study horization will be cond /r – ombitasv otocol Con de AbbVie is p v 1.0 dated 26.0 Real Wo – Ombita Chronic H Observat P15-743 n.a. What is t productiv interferon Dasabuv setting ac Russian AbbVie ucted in co local reg vir and dasab nfidential Inform ermitted witho 06.2015 rld Evidenc asvir, ± Dasa Hepatitis C tional, Multi , version 1.0 the effective vity and hea n-free regim vir, ± Ribavir cross clinica Federation e Ltd ompliance gulatory req buvir mation ut prior written e of the Effe abuvir, ± Ri in the Russ -Center Stu 0 dated 26.0 eness, patie althcare reso men of Parita rin in patien al practice p with this p quirements n authorization ectiveness o bavirin in P sian Federat udy 06.2015 ent reported ource utiliza aprevir/r – O ts with CHC patient popu rotocol and s from AbbVie Pag of Paritapre atients with tion- An outcomes, ation of the Ombitasvir, C in a real lif ulations? d all applic ge 1 of 61 evir/r work ± fe cable NCT02669940
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Versio
Titl
Titl
ProIdeDatProResObj
CoMa
MaHo
Th
No use or on 3.0 (22 Apr 2
e Page
le
otocol Versioentifierte of Last Veotocol search Quesjectives
untry(-ies) oin Author
rketing Authlder(s)
his study w
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
on
ersion of
stion and
of Study
horization
will be cond
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
Real Wo– OmbitaChronic HObservat
P15-743
n.a.
What is tproductivinterferonDasabuvsetting acRussian
AbbVie
ucted in colocal reg
vir and dasab
nfidential Informermitted witho
06.2015
rld Evidencasvir, ± DasaHepatitis C tional, Multi
, version 1.0
the effectivevity and hean-free regimvir, ± Ribavircross clinicaFederation
e Ltd
ompliance gulatory req
buvir
mation ut prior written
e of the Effeabuvir, ± Riin the Russ-Center Stu
0 dated 26.0
eness, patiealthcare resomen of Paritarin in patienal practice p
with this pquirements
n authorization
ectiveness obavirin in P
sian Federatudy
06.2015
ent reported ource utilizaaprevir/r – Ots with CHC
patient popu
rotocol ands
from AbbVie Pag
of Paritapreatients withtion- An
outcomes, ation of the Ombitasvir, C in a real lifulations?
mation ut prior writtenn authorization from AbbVie
Pagge 8 of 61
Versio
4.0
TitleReal in PaStudRatioThe (ABBshowexcluThe FedeThe ABBVsettinmeasenvirachieexcluper lowith EffectheremakeThis RBVclinicDurinstandrespopatiemostpegIFwereobsepredassisfutureThe genouse aof ad
No use or on 3.0 (22 Apr 2
: World Evideatients with Cy onale and Binterferon-fre
BVIE REGIMwn to be safeusion criteria ABBVIE RE
eration for therationale forVIE REGIMEngs, which msure of theronment, suceves its intenusion criteria ocal label whsignificant coctiveness resefore be morers. observationa, used accor
cal practice png the last ddard of careonse and th
ent care for Ct likely to resFN/RBV and
e not predictivervational stuictive factorsst in further oe. label of the
otype/subtypeand outcomedherence on
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Abstra
ence of the EChronic Hepa
ackground:ee combinatiEN) ± ribavie and effectiunder well cGIMEN is exe treatment or this observEN as demonmeans evalu capacity o
ch as in a rannded effect in
and will invohich might incomorbid condsearch allowsre relevant fo
al study is thrding to locapatient populadecade whene for the treahe subsequeCHC. As a pond. Interes first generatve of outcom
udy may plays of responseoptimizing tre
e ABBVIE Re and stage oe in daily clin
treatment o
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
act
Effectivenessatitis C in the
on regimen orin (RBV) forve in random
controlled conxpected to bof CHC in 20vational studynstrated in puating its efof a treatmendomized conn the usual clolve the broaclude patientditions and cos for externaor health-car
he first effectl label, undeation. n dual theraatment of CHent developmconsequencestingly, manytion direct ac
me in the devy an importae that are impeatment with
REGIMEN ± of liver disea
nical practiceutcomes in e
vir and dasab
nfidential Informermitted witho
06.2015
of Paritapreve Russian Fe
of Paritaprevr the treatmemized contronditions. be first availa15. y is to deter
pivotal trials tffectiveness. ent to prodntrolled trial, linical settingader patient pts with heteroould be used
al patient-, prre decisions
iveness reseer real world
py with pegyHC, the discment of treate, treatment y of the now cting anitviralsvelopment triant part in briportant in reah the interfer
RBV will vaase. It is there. In addition,everyday set
buvir
mation ut prior written
vir/r – Ombitaederation – A
vir/r – ombitaent of chronicolled clinical
able IFN-free
rmine how thtranslates intWhereas ef
uce the deeffectiveness
g. Effectivenepopulations iogenous comd to model anrovider-, and by both pro
earch examinconditions in
ylated interfecovery of pretment algoritcould be ef
well establiss (DAAs) in cals of the ABidging the daal world treatron-free ABB
ary accordingefore relevan this study wttings, which
n authorization
asvir, ± DasaAn Observat
asvir with or wc hepatitis C trials with st
e combinatio
he efficacy ato real world fficacy can
esired effect s is the exteness trials typiin routine clin
mpliance pattnd dissemina
system-leveviders in pra
ning the ABBn the Russia
eron (pegIFNedictive factothms markedffectively targ
shed predictocombination
BBVIE REGIMata gaps. It tment settingBVIE REGIM
g to hepatitint to understawill provide da
may help tre
from AbbVie Pag
abuvir, ± Ribational, Multice
without dasa(CHC) has
trict inclusion
on in the Rus
and safety oeveryday clbe defined
in a contrnt to which a cally have limnical practiceerns and pat
ate best practel factors andactice and po
BVIE REGIMn Federation
N) plus RBVors for virolod a milestongeted to pat
ors of responwith pegIFN/
MEN ± RBV.may help ides and thus, cEN ± RBV in
s C virus (Hand the patteata on the imeating physic
ge 9 of 61
avirin enter
abuvir been
n and
ssian
of the inical as a rolled drug
mited e and tients tices. d can olicy-
EN ± n in a
V was ogical ne in tients se to /RBV This
entify could n the
HCV) ern of mpact cians
Versio
to imThe outcoin a rReseWhautilizasettin Prim
Seco
StudThis ABBVThe local preceTargPatie
VariaPrim
No use or on 3.0 (22 Apr 2
mprove the maaim of this oome, work prreal world seearch Questt is the effecation of the ng across clin
ary Objective1. To d
ABBVvirolo
ondary Objec2. To pr3. To co
popu4. To de5. To d
produ6. To d
utilizady Design:
is a prospecVIE REGIMEprescription clinical praedes the dec
get Populatioents are eligib Treatmen
genotypeRBV acco
If RBV iswith the contraind
Patients study
Patient mtherapeu
ables: ary Variable The perc
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
anagement oobservationalroductivity antting across tion and Objctiveness, painterferon-fre
nical practice
e describe in VIE REGIMogical responctives rovide real wollect informa
ulation escribe the to
document theuctivity in theetermine theation
ctive, multi-cEN ± RBV. of a treatme
actice and lacision to offeron:ble for observnt-naïve or -e 1, receivingording to stas co-adminiscurrent loca
dication durinmust volunta
must not be ptic trial
centage of pa
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
of patients un study is to pnd healthcareclinical practjectives:
atient reporteee ABBVIE e patient pop
routine clinicEN ± RBV
nse at 12 wee
world evidencation on co-m
olerability of e effect of te Russian poe impact of th
center observ
ent regimen isabel, is madr the patient t
vation in this-experiencedg combinationndard of care
stered with thal label (withng pregnancyarily sign and
participating o
atients achiev
vir and dasab
nfidential Informermitted witho
06.2015
nder their carprovide evidee resource utice patient po
d outcome, wREGIMEN ±ulations?
cal practice in patients
eks after end
ce for predictimorbidities an
the ABBVIE the ABBVIE pulation he ABBVIE R
vational stud
s at the discde independthe opportun
s cohort if thed adult male n therapy wite and in line he ABBVIE R special atte
y) d date an in
or intending t
ving SVR12
buvir
mation ut prior written
re. ence of the etilization of thopulations.
work product± RBV in pat
the effectivwith CHC
d of treatmen
ve factors ofnd concomita
REGIMEN ±REGIMEN
REGIMEN ±
dy in patients
retion of the dently from tity to particip
e following apor female p
th the interferwith the currREGIMEN, itention to con
formed cons
to participate
(HCV RNA <
n authorization
effectivenesshe ABBVIE R
tivity and heatients with C
veness of thas evidencet (SVR12)
f virological reant medicatio
± RBV ± RBV on
RBV on hea
s receiving th
physician inthis observapate in this st
pplies: patients with ron-free ABBrent local labt has been pntraception r
sent prior to
in a concurr
<50 IU/mL 1
from AbbVie Page
s, patient repREGIMEN ±
althcare resoCHC in a rea
he interferoned by susta
esponse on in the Rus
PROs and
althcare reso
he interferon
n accordanceational study tudy.
confirmed CBVIE REGIMel prescribed inrequirements
inclusion into
rent intervent
2 weeks [i.e
e 10 of 61
orted RBV
ource al life
n-free ained
ssian
work
ource
n-free
e with y and
CHC, EN ±
n line s and
o the
tional
. ≥70
Versio
DataSourdata StudIn phat leaexpeREGpopu
As owidthleastenro
DataThe abovtheir labelsufficRNA≥50 but ndue tinform(eCRpopuREGDescbasegrouare rweekinto specThe
No use or on 3.0 (22 Apr 2
days] afte Secondar Co-morb Serious a Question
work proinitiation,
PAM-13, a Sources: rce documenin his/her ow
dy Size: hase III studiast 90% wer
erienced patieGIMEN ± RBulation of this
bvious from Th of the 95%t 95%, then 9lled during th
a Analysis: core populat
ve), who havedisease cha
will be summcient follow-u
A data ≥70 daIU/mL at theno HCV RNAto reasons remation (e.g.
RF) but dateulation (SP)
GIMEN. criptive and eeline and diseps (based onrelevant for sks). In additiosubgroups.
cified in the stprimary effe
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
er the last acry Variables idities and coand non-serionnaires on PRoductivity an at EoT as wPSP satisfac
nts are definewn patient file
es investigatre observed, ents). To deV in patients
s study should
Table 3, if th% confidence94 patients ahe inclusion p
tion (CP) is de started thearacteristics.marized in thup data (CPSays after the e last measurA measuremelated to safevirologic fail
AAs targetinrotease inhionavir, an c enhancer esults in higr (ABT-267), and dasablar potency
h or withoued patients
EARL-IV [59
esulted in th
E REGIMEN
L-IV)
L-III)
L-II)
mal regimenequire RBV.
GIMEN in tholled exclusind treatmentth RBV and
e 17 of 61
ng bitor
of gher ) is a buvir in
t RBV
9],
he
N alone
for
e ively t-
d were
Versio
randSVRdemto th12 w93%resptreatrespweehighand
The Phascirrhtolermanof Rcom(ALTdysfthe ccontwith ALT obseof thby pof treBiliruof in
Resptreatombwitho
Thesmigh
No use or on 3.0 (22 Apr 2
domized to 1R following tmonstrated th
e subgroupweeks who a% when treatponders andtment group
ponders andks is require across all s24 weeks.
ABBVIE REse III trials a
hosis. Basedrated with a y of the AEBV. Howevebination wit
T) elevationsunction andcases were traceptives ocontinuatioelevation. T
erved in sube bilirubin taritaprevir aeatment, peubin elevatiodirect bilirub
ponse of CHtment-naīve
bitasvir with out RBV [61
se results frht provide p
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
12 or 24 wereatment fohat the smap of genotypachieved anted for 24 w
d relapsers hp, while simid relapsers ted only for csubgroups i
EGIMEN haacross a vard on Phase low disconts and laborer, these AEth interferons were obse
d generally rin women oor hormone
on or brief inTransient elbjects receivransportersand RBV-indeaked by stuons were nobin elevatio
HC genotype patients wvs. without
1]. No seriou
rom pivotal shysicians w
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
eeks of therar 12 or 24 w
all differencepe 1a treatmn SVR of 80
weeks. Amonhad higher Silar SVR rattreated for 2cirrhotic genn genotype
as been studriety of patieIII data, thetinuation ratratory abnorEs were mun. Transient,erved at a loresolved witon concurre replaceme
nterruption olevations in ving the ABBs, organic anduced hemoudy Week 1ot associatens was lowe
pe 4 was assere randomRBV for 12us SAEs or
studies are with the arma
vir and dasab
nfidential Informermitted witho
06.2015
apy. Overallweeks, respe in SVR be
ment-experie0%. This subng genotypeSVR rates ttes were see24 weeks, snotype 1a n 1b treatme
died with anent populatie ABBVIE Rte. Adverse rmalities repuch milder th, asymptomow rate, werth ongoing t
ent ethinyl esnt) and disc
of the ABBVserum biliruBVIE REGInion-transpoolysis. Biliru, and gener
ed with aminer among s
sessed in thmized to the
weeks. TheAEs leadin
encouraginamentarium
buvir
mation ut prior written
l 92% and 9ectively. An
etween treatenced prior bgroup of pae 1a infectehan null resen among tuggesting thull responde
ent-experien
nd without Rons includin
REGIMEN, wevents (AE
ported were han observe
matic serum re not assoctreatment. Astradiol-concontinuationVIE REGIMEubin (predomMEN with Rorting polypubin elevatiorally resolvenotransferasubjects who
he phase II 2 DAA come SVR was g to discont
ng and the nm to cure the
n authorization
96% of patienalysis of sutment arms null respondatients achid patients,
sponders in he null resphat the longers. SVR ra
nced patient
RBV in over ng those witwith or withoEs) were typ
attributableed when RBalanine amciated with A disproportntaining thern of the hormEN led to resminantly ind
RBV, relatedeptides (OAons occurreed with ongose elevationo did not rec
study PEARmbination of
100% with tinuation we
new interferoe vast major
from AbbVie Page
ents achieveubgroups was due larders treatedeved an SVpartial the 12 wee
ponders, pager durationates were vets treated fo
2,300 patieth compens
out RBV, wapically mild, e to the presBV was giveinotransferahepatic tionate numrapy (i.e., monal therasolution in sdirect) wered to the inhibATPs) 1B1/1d after initiaoing therapyns. The freqceive RBV.
RL-I in whicParitaprevirRBV vs. 91
ere reported
on-free regirity of patien
e 18 of 61
ed
rgely d for VR of
ek rtial of 24
ery or 12
ents in sated as well and sence en in ase
ber of
py serum bition 1B3, ation y. uency
h 86 r/r – %
d.
mens nts
Versio
infecthesthe fevertreat
7.2
The effecunde
The Russ
The the Aeveras aenviwhictrialspopupatiecondresetheremak
ThisREGRuss
Durithe tfollowstudlikelyvirolotreatfor th
No use or on 3.0 (22 Apr 2
cted with CHe results trafirst proteasryday life ant patient sub
ABBVIE REctive in rander well contr
ABBVIE REsian Federa
rationale foABBVIE REryday clinica measure oronment, su
ch a drug acs typically haulations in roents with heditions and cearch allowsefore be rele
kers [65].
observatioGIMEN ± RBsian Federa
ng the last dtreatment ofwing the disies with largy to respondogical cure.tment exposhe eradicati
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
HC. Howeveanslate into se inhibitors nd especiallybgroups tha
Rationa
EGIMEN ± Rdomized conrolled condi
EGIMEN is ation for the
or this obserEGIMEN as al settings, eof the capacuch as in a rchieves its inave limited outine clinic
eterogenouscould be uss for externaevant for he
nal study is BV, used acation in clinic
decade whef CHC, manscovery of pge data basd and futile . HCV genosure and onon of HCV
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
er, the mediroutine clinwhich werey the tolerab
an expected
ale
RBV for thentrolled clinitions.
expected totreatment o
rvational studemonstratevaluating itity of a treatrandomizedntended effeexclusion c
cal practice,s compliancsed to modeal patient-, pealth-care d
the first efccording to lcal practice
en dual thernagement ofpredictive fases [66]. Thutreatment s
otype and sun-treatment in everyday
vir and dasab
nfidential Informermitted witho
06.2015
ical commuical practice
e available tbility was fa from the de
e treatment oical trials wi
o be first IFNof CHC in 2
udy is to detted in pivotats effectiventment to pro
d controlled ect in the us
criteria and w treated pere patterns a
el and dissemprovider-, anecisions by
fectiveness ocal label, u patient pop
rapy with pef patients an
actors of virous treatmenstopped in pubtype, basevirological r
y clinical pra
buvir
mation ut prior written
nity is expee particularlto physicianar less favorevelopment
of CHC hasth strict incl
N-free comb015.
termine howal trials transness. Whereoduce the dtrial, effectivsual clinical will involve tr local labeland patientsminate bestnd system-le both provid
research exunder real wpulation.
egIFN plus Rnd clinical oological respnt could be tpatients witheline viral loresponse practice [27]. M
n authorization
cting data wy after the e
ns and wherrable in certat trials [62] [6
s been showlusion and e
bination ava
w the efficacslates into reas efficacyesired effecveness is ‘thsetting’ [64
the broader, which mig
s with signifit practices. evel factorsders in pract
xamining theworld condit
RBV was staoutcome weponse, oftentargeted to ph a low likelioad, fibrosisroved to be More recent
from AbbVie Page
which show experience wre the outcoain difficult-63].
wn to be safeexclusion cr
ailable in the
cy and safetreal world y can be defct in a controhe extent to
4]. Effectivenr patient ht include icant comorEffectivenes and can tice and pol
e ABBVIE tions in the
andard of cre improvedn in observapatients mohood of
s stage, ageuseful predtly the disco
e 19 of 61
how with me in
-to-
e and riteria
e
ty of
fined olled
o ness
rbid ss
licy-
are for d ational ost
e, ictors
overy
Versio
of a (SNPFor nresprespobseidennot dwith
The stagoutcadhephys
The repoREG
8.0
8.1
Wharesoin a
8.2
8.2
1
8.2
2. To
No use or on 3.0 (22 Apr 2
genetic dispP) contributnew interfer
ponse is extrponse were ervational sttify predictivdetected in the interfer
label of thee of liver dis
come in dailyerence on trsicians to im
aim of this orted outcomGIMEN ± RB
at is the effeource utilizatreal life sett
2.1
1. To descABBVIE
2.2
o provide re
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
position of ted further toron-free trearemely sparnot initially tudy may plve factors ointervention
ron-free ABB
e ABBVIE Rsease. It is ty clinical prareatment ou
mprove the m
observationme, work proBV in a real
Resea
Resear
ectiveness, ption of the inting across
Objecti
Prima
ribe in routi REGIMEN
Secon
eal world ev
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
the Interleuko our underatment regimrse and sevidentified thay an impo
of virologicalnal trials andBVIE REGIM
EGIMEN wtherefore reactice. In adutcomes in emanagemen
nal study is toductivity anworld settin
arch Que
rch Questi
patient reponterferon-freclinical prac
ives
ary Objecti
ne clinical p ± RBV in p
ndary Obje
idence for p
vir and dasab
nfidential Informermitted witho
06.2015
kin 28B (IL2rstanding of mens know
veral of the nhrough analyrtant part inl response id which couMEN in the
ill vary accoelevant to unddition, this everyday sent of patient
to provide end healthcang across cl
stion and
on
orted outcomee ABBVIE ctice patient
ive
practice the patients with
ectives
predictive fa
buvir
mation ut prior written
28B) single nvirological ledge of prenow well estyses of the bridging thn everyday
uld be used future.
ording to HCnderstand thstudy will p
ettings, whicts under the
evidence of are resourceinical practi
d Object
me, work proREGIMENt population
effectiveneh CHC as ev
actors of viro
n authorization
nucleotide presponses t
edictive facttablished prdevelopmee data gapsclinical settto further op
CV genotypehe pattern o
provide datach may helpeir care.
the effectivee utilization oice patient p
tives
oductivity a± RBV in pa
ns?
ss of the intvidenced by
ological resp
from AbbVie Page
polymorphisto treatmentors of viroloredictors of nt trials. Ths and could tings which ptimize trea
e/subtype aof use and on the imp
p treating
eness, patieof the ABBVpopulations.
nd healthcaatients with
terferon-freey SVR12
ponse
e 20 of 61
sm t [67].
ogical
is help were
atment
and
act of
ent VIE .
are CHC
e
Versio
3. Topopu4. To5. Toprod6. Toutiliz
9.0
9.1
Thisfree at thmadpatie
AdulREGclinic
Afterdatalabodocuwill bweeuniqonce
Thisprocobsedocu
Thistreat
No use or on 3.0 (22 Apr 2
o collect infoulation o describe to documentductivity in tho determinezation
is a prospeABBVIE REe discretione independ
ent the oppo
lt patients cGIMEN will bcal visit at th
r written infoa, HCV disearatory asse
umentation)be observedks after treaue patient n
e the investi
study is foccedures andervational stumented wil
12-week 24-week
schedule istment for CH
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
ormation on
the tolerabilt the effect ohe Russian e the impact
Resea
Study D
ective, multiEGIMEN witn of the physently from t
ortunity to p
hronically inbe offered thhe participa
ormed consase charactssments as
) will be docd for the duratment comnumber will igator or de
cusing on cod diagnostic tudy period ll be those c
k treatment k treatment
s based on HC.
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
n co-morbid
ity of the ABof the ABBVpopulation
t of the ABB
arch Meth
Design
-center obsth or withousician in accthis observaarticipate in
nfected withhe opportun
ating sites.
sent has beeteristics, co-s recorded incumented inration of thepletion. No be automatsignee crea
ollecting reamethods wentails the
closest to th
regimen: foregimen: fo
the anticipa
vir and dasab
nfidential Informermitted witho
06.2015
ities and co
BBVIE REGVIE REGIME
BVIE REGIM
hods
ervational sut RBV. Thecordance w
ational studyn this study.
h HCV, recenity to partic
en obtained-morbiditiesn the patien the electro
e ABBVIE Rpatient identically allocaates a new p
al-world datwill follow ph
following dahe time wind
our visits pluour visits plu
ated regular
buvir
mation ut prior written
oncomitant m
GIMEN ± RBEN ± RBV o
MEN ± RBV
study in patie prescriptiwith local cliny and prece
eiving the intcipate in this
, patient das, co-medicant's medical nic case rep
REGIMEN thntifiable infoated by the wpatient file.
a. Follow-upysicians’ roata collectiodows as ind
us two interimus three inte
r follow-up fo
n authorization
medication i
BV on PROs an
on healthca
ents receivion of a treatmnical practicdes the dec
terferon-frees study durin
ta includingation, treatmrecords (soport form (eherapy and formation willweb based
p visits, treautine clinica
on schemesicated in Fig
m data colleerim data co
or patients u
from AbbVie Page
in the Russi
nd work
are resourc
ing the interment regime
ce and labelcision to offe
e ABBVIE ng a routine
g demograpment details,ource eCRF). Patiefor up to 24l be captureeCRF syste
atment, al practice. T, data gure 1:
ection windoollection win
undergoing
e 21 of 61
ian
e
rferon-en is , is er the
e
hic , and
ents 4 ed, a em
The
ows dows
Versio
Figu
9.2
For o9.1 a
9.2
Patie
No use or on 3.0 (22 Apr 2
ure 1 - Stud
overall reseand 9.4.1 as
2.1
ents are elig
TreatmeCHC, geREGIMElabel
If RBV isline withrequirem
Patientsstudy
Patient minterven
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
dy Flowcha
Setting
earch designs well as to
Targe
gible for obs
ent-naïve or enotype 1, rEN ± RBV a
s co-admini the current
ments and c
s must volun
must not betional thera
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
art
g
n and obserFigure 1.
t Populati
servation in
-experiencereceiving coaccording to
stered with t local label
contraindicat
ntarily sign a
e participatinpeutic trial
vir and dasab
nfidential Informermitted witho
06.2015
rvational doc
on
this cohort
ed adult maombination to standard o
the ABBVIE(with speciation during p
and date inf
ng or intend
buvir
mation ut prior written
cumentation
if the follow
ale or femaleherapy with
of care and i
E REGIMENal attention pregnancy)
formed cons
ing to partic
n authorization
n schedule
wing applies
e patients wh the interferin line with t
N, it has beeto contrace
sent prior to
cipate in a c
from AbbVie Page
refer to Sec
:
with confirmeron-free ABthe current l
en prescribeeption
o inclusion in
concurrent
e 22 of 61
ctions
ed BBVIE local
ed in
nto the
Versio
9.2
Thismonwee
The maxpatie48 w
9.2
For pEoT be dthe eSect
If, inSVR
9.2
UnivmanAbbVrepreand instit
No use or on 3.0 (22 Apr 2
2.2
is a prospeths and theks post-trea
observationx. 36 weeks ents receivinweeks (24 w
2.3
patients wheCRF pageocumented
event must tion 11.5).
such patienR12 and SVR
2.4
versity centeagement ofVie Affiliate esentative otheir availatute will be d
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Study
ective, obsee observatioatment.
nal period fo(12 weeks tng 24 week
weeks treatm
Termi
o terminatee should be. If the reasbe reported
nts, there isR24 pages
Invest
ers and outpf patients wiMedical Dir
of the medicbility of the documented
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
y Duration
rvational stunal period o
or patients rtreatment as of ABBVIE
ment and 24
nation Cri
the ABBVIe filled in andson for ABBVd to AbbVie
s evidence oshould be c
tigator Sel
patient clinicith CHC willrector will ecal practice target patied in the eCR
vir and dasab
nfidential Informermitted witho
06.2015
udy. The incof the study
receiving 12and 24 weekE REGIMEN
4 weeks pos
iteria
E REGIMENd the reasonVIE REGIMwithin 24 ho
of virologicacompleted if
lection Cr
cs qualified l be selectensure that sin the coun
ent populatioRF.
buvir
mation ut prior written
clusion periwill be from
2 weeks of Aks post-treatN the observst-treatment
N prematuren for treatm
MEN discontours of phys
al response f respective
iteria
by training d to participsites participtry, have th
on. The type
n authorization
od will be am baseline v
ABBVIE REtment obsevational pert observatio
ely for whatent disconti
tinuation is dsician aware
during theradata is ava
and experiepate in this spating in thee ability to c
e of the part
from AbbVie Page
pproximatevisit until 24
GIMEN willrvation) andriod will be mn).
tever reasoninuation shodue to an Seness (see
apy or at Eoailable.
ence in the study. The e study are conduct theticipating tre
e 23 of 61
ly 8
be d for max.
n the ould AE,
oT, the
e study eating
Versio
9.3
9.3
9.3
• C
• S
• Qworkinitia
• P
9.4
Sourpatieare cmeddocu
The ethicdirec
9.4
Thison d
Afterthe erouti
No use or on 3.0 (22 Apr 2
3.1
The [i.e. ≥
3.2
Co-morbidit
Serious and
Questionnaik productivitation, at EoT
PAM-13, PS
rce documeent data in hcollected froical records
umentation
investigatorcs committect access to
4.1
observatioata to be co
r the patienteCRF, if avaine clinical p
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Variabl
Prima
percentage≥70 days] a
Secon
ies and con
d non-seriou
ires on PROty and activiT as well as
SP satisfacti
Data So
ents are defihis/her own om the sours containingand laborat
r(s)/institutioee/- review bo source dat
Data t
nal study coollected thro
t has signedailable frompractice.
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
es
ary Variabl
e of patientsafter the last
ndary Vari
ncomitant m
us adverse e
Os: EuroQolity impairme 12 and 24
ion and utili
ources
ined as origpatient files
rce documeg demographtory assessm
on(s) will peboard (IEC/ta documen
to be Docu
overs three oughout the
d informed c the patient
vir and dasab
nfidential Informermitted witho
06.2015
e
achieving St actual dos
ables
edication
events and
l 5 dimensioent (WPAI) weeks after
zation ques
ginal docums which will nts for eachhic data, mements.
ermit study-rIRB) review
nts.
umented
documenta study is su
consent, thet charts base
buvir
mation ut prior written
SVR12 (HCe of the AB
pregnancy
on 5 level (Equestionnair EoT
stionnaires
ents. The inserve as so
h patient in tedical, treat
related monw, and regula
ation periodsmmarized i
e following ded on asses
n authorization
CV RNA <50BVIE REGI
occurrence
EQ-5D-5L) qire prior to t
nvestigator wource data fothe study, ctment and d
nitoring, audatory inspec
s, see Figurn Table 2.
data will be ssments do
from AbbVie Page
0 IU/mL 12 wMEN)
s
questionnaitreatment
will documeor the study
consisting ofdiagnostic
dits, indepenction(s), pro
re 1. An ove
documentene in physic
e 24 of 61
weeks
re and
ent y. Data f
ndent oviding
erview
ed in cians’
Versio
9.4.
The
No use or on 3.0 (22 Apr 2
1.1
following w
Demograo I
CHC diso Yo S
CHC treo No If
Relevan Concom ABBVIE Laborato
Key clin AL(alani AS(aspa
γ-G(gam To Alb Cr AF
Key hem Hb Pla Pro
Virology HC HC
HIV-infe CD(clust HIV
*derive#by Coc
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Inclusio
will be docum
aphic informnterleukin 2
sease charaYear of diagStage of liveatment histo
Naïve or expf experience
nt medical hmitant medic
REGIMENory data ical chemistry
LT ine-aminotrans
ST artate-aminotra
GT ma-glutamyltra
otal bilirubin bumin reatinine FP
matology b (Hemoglobinatelets othrombin time
CV genotype aCV RNA
cted patients oD 4 count ter of differentiV RNA
ed from patient’sckcroft-Gault-Fo
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
on Docum
mented:
mation 28B (IL28B)acteristics gnosis and mer fibrosis ory perienced ed, most recistory, co-mation, see 9 ± RBV
sferase)
ansferase)
ansferase)
)
e
and subtype
only
ation 4)
s age, ALT, ASTormula based on
vir and dasab
nfidential Informermitted witho
06.2015
mentation
genotypes
mode of infe
cent prior thmorbidities a9.4.1.5
Remarks including upp
including ULNAST to platel(FIB-4)* will b
creatinine cle
or internation
quantitative/ qreaction (PCR
most recent a
in copies/mL
T and plateletsn creatinine, gen
buvir
mation ut prior written
ection
herapy and nd co-infect
per limit of norm
N, et ratio index be calculated
earance# will b
nal normalized
qualitative HCR) test, see 9.4
assessment
nder, age and w
n authorization
outcome tions
mal (ULN),
(APRI) and Fi
be calculated
ratio (INR)
CV RNA by pol4.1.4
weight
from AbbVie Page
brosis-4 Score
ymerase chain
e 25 of 61
e/Index
n
Versio
9.4.
Follotreatprac
The
9.4.
Follotreatprac
No use or on 3.0 (22 Apr 2
Patient q PAM-13 Treatme
1.2
ow-up visits tment, proce
ctice.
following w
LaboratoKey clin
AL AS
γ-G To Cr
Key hem Hb Pla
Virology HC
HIV-infe CD HIV
Concom Adheren
taken an Tolerabi Patient q PSP sat Treatme
1.3
ow-up visits tment, proce
ctice.
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
questionnai
ent related h
During
are scheduedures and
will be docum
ory data ical chemistry
LT ST
GT otal bilirubin reatinine matology b atelets
CV RNA cted patients o
D 4 count V RNA
mitant medicnce to ABBVnd RBV Y/Nlity (sAEs aquestionnaitisfaction anent related h
Post-Tr
are scheduedures and
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
res, see tab
health care r
Treatmen
uled by the pdiagnostic
mented:
only
ation, see 9VIE REGIME
N) and AEs, seeres see 9.4
nd utilizationhealth care r
reatment D
uled by the pdiagnostic
vir and dasab
nfidential Informermitted witho
06.2015
ble 2 and 9.4
resource uti
nt Docume
physician pemethods wi
Remarks including ULNincluding ULNAPRI and FIB creatinine cle quantitative/ q most recent ain copies/mL
9.4.1.5 EN ± RBV (
e 11.5) and.1.6
n questionnaresource uti
Document
physician pemethods wi
buvir
mation ut prior written
4.1.6
ilization
entation
er routine cill follow phy
N N, B-4 will be calc
earance will be
qualitative HC
assessment
(ABBVIE RE
pregnancie
aires; PAM-ilization
tation
er routine cill follow phy
n authorization
linical practysicians’ rou
culated
e calculated
CV RNA PCR t
EGIMEN - %
es (see 11.6
-13
linical practysicians’ rou
from AbbVie Page
tice. Likewisutine clinica
test, see 9.4.1
% of target d
6)
tice. Likewisutine clinica
e 26 of 61
se al
.4
dose
se al
Versio
The
No use or on 3.0 (22 Apr 2
following w
LaboratoKey clin
AL AS
γ-G To Alb Cr
Key hem Hb Pla Pro
Virology HC
HIV-infe CD HIV
Tolerabi
Patient q PSP Sat
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
will be docum
ory data ical chemistry
LT ST
GT otal bilirubin bumin reatinine matology b atelets othrombin time
CV RNA
cted patients oD 4 count V RNA
lity (sAEs, s
questionnaitisfaction an
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
mented:
e
only
see 11.4) an
res see 9.4nd utilization
vir and dasab
nfidential Informermitted witho
06.2015
Remarks including ULNincluding ULNAPRI and FIB creatinine cle or INR quantitative/ q
event that, ie resultedrvention haude an eveurred in a m
event that rany length
ergency rooity.
event thatpitalized an
anomaly deresults in fe
event that rrferes with ent. Disaberiences ofh as head
uenza, andle).
important mediately lif
pitalization, pardize the gical interveed above (ipitalization, genital ano
ability/incapantaneous aortant medude allergic
buvir
mation ut prior written
is consider
esults in the
n the opinio in immead not beent that wou
more severe
results in an of time.
om visit or
t occurs wd prolongs t
etected at oretal loss.
results in a the activitie
bility is nf relatively dache, na
d accidenta
medical fe-threateninbut based patient an
ention to prei.e. death o
prolongaomaly, or acity). Addabortion or ical event.c bronchos
n authorization
red a seriou
e death of a
on of the invediate fataen taken.
uld have beform.
n admissionThis does admission
while the sthe patient's
r after birth,
condition tes of daily not intendeminor medusea, vomal trauma
event thatng or resuon medica
nd may reqevent any oof patient, ation of
persistentditionally, a
stillbirth isExamples
spasm req
from AbbVie Page
us adverse
patient.
vestigator, wality if me
This doesen fatal if it
n to the hosnot includ
to an outpa
study paties hospital st
or any ano
hat substanliving of a sed to incical signific
miting, diar(e.g. spra
t may notult in deatal judgment quire medicof the outcolife threatehospitaliza
t or signifany electivs considere
of such evquiring inte
e 43 of 61
event
would edical s not t had
spital e an atient
nt is tay.
omaly
ntially study clude cance rrhea, ained
t be th or
may cal or omes ening, ation, ficant e or d an vents nsive
Versio
11.2
The endp
Mil
Mo
Sev
11.3
The prod
Re
NoPo
If nobe p
11.4
SAEuntil treat
No use or on 3.0 (22 Apr 2
2
following depoint/data p
ld:
oderate:
vere:
3
following dduct:
asonable P
ossibility
o reasonableprovided for
4
Es will be rep30 days or
tment.
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Severit
efinitions wipoint in the s
The A
The Ausua
The Aactiv
Relatio
definitions w
Possibility
Reasonab
e possibilitythe AE.
Serious
ported to Abr 5 half-live
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
treadyscinpadepe
ty
ill be used tstudy and fo
AE is transi
AE causes al activities.
AE causes ities and ma
nship to P
will be used
An AErelation
ble An AErelation
y of being re
s Adverse
bbVie from ts following
vir and dasab
nfidential Informermitted witho
06.2015
tment in ancrasias or atient hospitendency or
to rate the sor all SAEs.
ent and eas
the patient
considerabay be incapa
Pharmaceu
to assess
E where thenship betwe
E where thenship betwe
elated to pro
Event Co
the time thethe intake
buvir
mation ut prior written
n emergencconvulsion
talization, odrug abuse
severity for a
sily tolerated
discomfort
ble interfereacitating or
utical Prod
the relation
ere is evideen the prod
re is no eveen the prod
oduct is give
ollection P
e physician of the last d
n authorization
cy room or ns that door the devee.
any AE bein
d by the pat
and interru
nce with thelife threaten
duct
nship of the
ence to suduct and the
idence to sduct and the
en, an altern
eriod
obtains the dose of phy
from AbbVie Page
at home, bo not resulopment of
ng collected
tient.
upts the pat
e patient's uning.
AE to the
uggest a cae AE.
uggest a cae AE.
nate etiology
informed coysician-pres
e 44 of 61
blood ult in
drug
d as an
ient's
usual
use of
ausal
ausal
y must
onsent scribed
Versio
11.5
In th
In th
11.6
Patiedonatreatlabe
In thwithisyste
The Preg
12.0
At thworkfollowmethques
No use or on 3.0 (22 Apr 2
5
e event of a
● For AbbVbecoAbbV
● For Authbeco
e event of a
● For eby us
6
ents and thation througtment with Dl) and/or co
he event of ain 24 hoursem or notify
investigatognancy Reg
0
he end of king on bewed. This hodology astionnaires,
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Serious
an SAE, the
events fromVie authorizoming awarVie contact
events fromhorization Homing aware
a non-serio
events fromsing the eC
Pregna
heir partneghout the coDAAs only,
onsistent wit
a pregnancs of the phyying the Abb
r is encouraistry, if RBV
PlansResult
this observehalf of Ab
report will and its re
the final s
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
s and non-
e physician w
m patients uzed productre of the eperson iden
m patients uHolder (MAHe of the eve
ous AE, the
m patients usCRF system.
ancy Repo
rs should aourse of theor for 7 mo
th local treat
cy occurrencysician becobVie contact
aged to repV is included
for Dissts
vational studbVie. The
contain a esults and tudy output
vir and dasab
nfidential Informermitted witho
06.2015
-serious A
will:
using the At) report to Aevent by usntified in Se
using a nonH) of the prent.
physician w
sing the ABB.
rting
avoid pregne HCV treaonths after tment guide
ce in the paoming awart person ide
ort the pregd within the
eminatin
dy, a reporrequired sdescriptionconclusio
t and study
buvir
mation ut prior written
Adverse Ev
ABBVIE REGAbbVie withsing the eCection 11.0.
n-AbbVie prroduct withi
will:
BVIE REGI
nancy and atment and the last dos
elines for RB
atient, the phre of the prentified in Se
gnancy inforregimen.
ng and C
rt will be wtandard stun of the o
ons. The y report are
n authorization
vent Repo
GIMEN ± Rhin 24 hoursCRF system
roduct - notin 24 hours
MEN ± RBV
males shofor 30 daysse of RBV BV.
hysician wilregnancy byection 11.0.
rmation to t
Communi
written by Audy report objectives ocompleted
e the confid
from AbbVie Page
orting
RBV (or anys of the phy
m or notifyin
tify the Mars of the phy
V report to A
ould avoid s after the (or per loca
l report to Ay using the .
he voluntar
icating S
AbbVie or atemplate w
of the studeCRFs, p
dential prop
e 45 of 61
y other ysician ng the
rketing ysician
AbbVie
sperm end of
al RBV
AbbVie eCRF
ry RBV
Study
a CRO will be dy, the patient erty of
Versio
AbbVpressubm
The the Wthe publ
No use or on 3.0 (22 Apr 2
Vie and masentations) wmitted to loc
results of thWorld HealtICMJE (Inteications. Au
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
ay not be rwithout expcal authoritie
his study with Organizaernational Cuthorship wi
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
released to press writtenes by the pa
ll be made ation (WHO)Committee ll be in line
vir and dasab
nfidential Informermitted witho
06.2015
unauthorizn approval articipating c
publicly ava) Registry Nof Medical with ICMJE
buvir
mation ut prior written
zed people from AbbV
countries pe
ailable on onNetwork wh
Journal EdE’ authorship
n authorization
in any formVie. The stuer local laws
ne of the prich meet thditors) and p requireme
from AbbVie Page
m (publicatioudy results ws and regula
rimary registe requiremethrough sc
ents [68].
e 46 of 61
ons or will be ations.
tries in ents of cientific
Versio
13.0
[
[
[
[
[
[
[
[
[
[1[1
[1
[1
[1
[1
[1
No use or on 3.0 (22 Apr 2
0
[1] LozancauseGloba
[2] Chen Med S
[3] HoofnS21-9
[4] Di BisHepat
[5] PawloMicro
[6] Lavan107-1
[7] WHOhttp://w
[8] Szaboinfecti
[9] PereirC viru2013;
0] Euros1] Smith
genotHepat
2] US DPreveinfecti
3] HoughVirolo
4] GlobaorganJ Vira
5] WHOhttp://wacces
6] Prati proce
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
Refere
no R, Naghaes of death fal Burden of D
SL, MorganSci 2006; 3: 4nagle JH. Co9. sceglie AM. tology 2000; otsky JM. Hbiol Infect 20nchy D. Evolv5. . Weekly www.who.into SM, Bibbyion in Latin Ara LMMB, Maus infection in 13: 1-12.
surveillance 2 DB, Bukh Jypes and 67tology 2014;
Department oention. Recomion and HCVhton M. Hep
ogy (3rd ed). al surveillancized in collab
al Hepat 1999. www.who.int
ssed July 07, D. Transmisdures: a glob
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
ences
avi M, Foremfor 20 age gDisease Studn TR. The na47-52. ourse and ou
Natural hist31: 1014-8.epatitis C v
011; 17: 105-ving epidemi
epidemiolot/docstore/wey M, Yuan YAmerica. Annartelli CMT, Mn Brazil, 200
2003; 8 (5): 9J, Kuiken C,7 subtypes: u
59: 318-27.of Health anmmendations
V related chropatitis C virusPhiladelphiace and conboration with9; 6: 35-47.
HCV t/csr/disease2014.
ssion of hepbal review. J
vir and dasab
nfidential Informermitted witho
06.2015
man K, et agroups in 199dy 2010. Lanatural history
utcome of h
tory of hepa
virus: from d6. iology of hep
ogical recoer/pdf/2000/wY et al. The n Hepatol 201Moreira RC e5 through 20
99-118. et al. Expan
updated criter
d Human Ses for prevenonic disease. ses. In: Field: Lippincott -
ntrol of hepah the Viral He
geno/hepatitis/wh
atitis C virusHepatol 200
buvir
mation ut prior written
al. Global an90 and 2010
ncet 2012; 38y of hepatitis
epatitis C. H
titis C: its im
discovery to
patitis C virus
rd. 2000;wer7503.pdf.
epidemiolog12; 11: 623-3et al. Prevale009: a cross-
nded classificria and geno
ervices - Cetion and con CDC Repords BN, KnipRaven, 1996atitis C. Re
epatitis Preve
otypes. hocdscsrlyo20
s by blood t06; 45: 607-16
n authorization
nd regional 0: a systema80: 2095-128s C virus (H
Hepatology 2
mpact on cli
eradication
s. Clin Microb
75, 17-2 gic burden o35. ence and risk-sectional stu
cation of hepotype assignm
enters for Dintrol of hepart1998; 47: 1-e DM, Howl6: 1035-58.eport of a ention Board
Avail003/en/index
transfusions 6.
from AbbVie Page
mortality froatic analysis . CV) Infection
2002; 36 (Su
nical manag
in 40 years
biol Infect 20
28. Availab
of hepatitis C
k factors of hudy. BMC Inf
patitis C virusment web res
isease Contratitis C virus -39 ey PM, eds,
WHO Cons, Antwerp, B
able x2.html#geno
and other m
e 47 of 61
om 235 for the
n. Int J
uppl 1):
gement.
s? Clin
011; 17:
ble at
C virus
epatitis fect Dis
s into 7 source.
rol and (HCV)
, Fields
ultation elgium.
at ome;
medical
Versio
[1
[1
[1
[2[2
[2
[2
[2
[2
[2
[2
[2
[2
[3
[3
[3
No use or on 3.0 (22 Apr 2
7] CentraamonRecomhttp://wnew-e
8] Albert(Supp
9] Alazacompe2010;
20] Brown21] Villano
impor29: 90
22] Thominfecti
23] Dore burde2014;
24] Davis chron
25] Strademana
26] Diensreview
27] Ghanymana
28] Backurisk of9: 509
29] Van drespoadvan
30] Everspegintcompe
31] Poynaand r2002;
32] ShiffmvirologHepat
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
al and Eastg drug usmmendationswww.aidsact
eu-member-sti A, Chemelpl 1): 17-24. wi W, Cunnensated cirrh 32: 344-55. n RS. Hepatito SA, Vlahovrtance of long08-14. as DL, Asteion: host, viraGJ, Ward J,
en (Guest Ed 21 (Suppl 1GL, Albrigh
ic hepatitis Cer DB, Wrighgement, and
stag LJ, McHw on the many MG, Stradegement, and
us LI, Boothrf all-cause m9-16. der Meer AJ,nse and al
nced hepatic son GT, Balaterferon alfa-ensated cirrhard T, McHuribavirin on l 122: 1303-1
man M, Hofmgic and histotology 1997;
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
tern Europeasers in ths for actiotioneurope.ostates-and. lo L, Benveg
ingham M, Dhosis due to
tis C and livev D, Nelson g-term follow
emborski J, al, and enviroThursz M. H
ditors Mark ): 1-4.
ht JE, Cook C in the Uniteht T, Thoma
d treatment ofHutchison JGnagement of er DB, Thom
d treatment ofroyd DB, Ph
mortality in pa
, Veldt BJ, Fl-cause morfibrosis. JAM
art L, Lee SS-2a monothehosis. Alimenutchison JG, iver fibrosis 3.
mann CM, Thologic respo26: 780-5.
vir and dasab
nfidential Informermitted witho
06.2015
an Harm Rehe new Eon. CEEHRrg/clearingho
gnù L. Natura
Dearden J, o chronic hep
er transplantaKE, Cohn S
w-up after ac
Rai RM, et onmental facHepatitis C diThursz, Gre
SF, Rosenbed States. Livas DL, Seeff f hepatitis C.G. Americanhepatitis C. G
mas DL, Seeff hepatitis C:illips BR, et
atients with h
Feld JJ, et alrtality amon
MA 2012; 308S, et al. Hisrapy in patie
nt PharmacolManns M, ein patients
hompson EBnse during i
buvir
mation ut prior written
eduction NeU member
RN brochurouse/topics/h
al history of
Foster GR.patitis C infe
ation. Nature, Thomas DLcute hepatitis
al. The natuctors. JAMA 2isease burde
egory Dore a
berg DM. Prover Transpl 2
LB. AASLD Hepatology n gastroenteGastroenteroff LB. AASLD an update. Hal. A sustain
hepatitis C. C
l. Associationng patients 8: 2584-93. tological bennts with hepa Ther 2008;
et al. Impact with chronic
B, et al. Relainterferon tre
n authorization
etwork (CEEr states are/leaflet 20hepatitis-c-am
hepatitis C.
Systematic rection. Alime
e 2005; 436: 9L. Persistencs C infection
ural history o2000; 284: 45en and strateand John Wa
ojecting futu2003; 9: 331-8D practice gu
2004; 39: 11erological asology 2006; 1D practice guHepatology 2ned virologic
Clin Gastroen
n between swith chronic
nefits of viroatitis C and a27: 542-51. of pegylate
. Hepatologysceglie AM, terferon to itis C: resultT-C) trial. Hema C, Di Boogy in chron 39: 333-42.
utchison JG,ination with entional The
em S, Feinmitis C. NEJMard T, McHuination interfeients with chMW, Shiffm
p). PeginterfM 2002; 347:
s M, McHutared with intandomized tryannis SJ, Sination therabavirin dose
bson IM, Mcterferon and
e 3 ADVANCman KE, Flamb and ribavirachieved an . Hepatologydad F, McConb/ribavirin (PNT-2 final res
L Recommen16/j.jhep.201
LD. Recommevailable at htt
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
ni T, Colombed with improy 2007; 45: 57
Shiffman Mprevent comts of the hepatology 200ona D, Scheic hepatitis C
, Gordon Sribavirin as
erapy Group. an SV, Rase 2000; 343: 1
utchison JG,eron alfa-2b ronic hepatit
man M, Redferon alfa-2a975-82. tchison JG, terferon alfa-rial. Lancet 2Sette H Jr,
apy in chronic. Ann Intern M
cHutchison Jribavirin in gE study. Hep
mm SL, Afdhrin for 24 or extended rap
y 2010; 52 (Sne J, Bacon
P/R) for treatsults. Hepatondations on 14.05.001 (Eendations fotp://www.hcv
vir and dasab
nfidential Informermitted witho
06.2015
bo M, et al. Soved outcom79-87.
M, Everson Gmplications opatitis C ant07; 46 (Suppepis F, et a
C: a meta-an
SC, Schiff Es initial treaNEJM 1998;
enack J, et al1666-72. Goodman Zplus ribavirinis C? Hepatody KR, et a
a plus ribavi
Gordon SC -2b plus riba2001; 358: 95Morgan TRc hepatitis CMed 2004; 1G, Dusheiko
genotype 1 Hpatology 201hal NH et al.
48 weeks inpid viral respuppl S1): 40BR et al. Bo
tment-naive pology 2010; 5Treatment opub ahead or Testing, M
vguidelines.o
buvir
mation ut prior written
Sustained virme in HCV-re
GT, et al. Pof advanced tiviral long-tel S1): 290A.al. Effect of nalysis of ind
ER, et al. Iatment for ; 339: 1485-9l. Peginterfer
Z, Ling MH,n regimen poology 2000; 3al (for the Pirin for chro
et al. PegIvirin for initia
58-65. et al. Pegin
C: a randomiz40: 346-55.
o GM et al. HCV treatmen0; 52 (Suppl Telaprevir in
n treatment-nponse: final r1A. ceprevir (BOpatients with52 (Suppl S1of Hepatitis
of print). anaging, and
org/sites/defa
n authorization
rological respelated cirrho
Prolonged anliver diseas
erm treatmen
peginterferoividual patien
nterferon alchronic hep
92. ron α-2a in p
Albrecht J.ossible for the31: 211-8. PEGASYS®
nic hepatitis
Interferon alfal treatment
nterferon-alphzed study of
Telaprevir int-naive patieS1): 427A.
n combinationnaive genotyresults of Pha
OC) combinedh hepatitis C ): 402A. C 2014. J
d Treating Hault/files/full_r
from AbbVie Page
ponse to intesis: a retros
ntiviral therapse associatent against c
on alfa-2a ont data. Hep
lfa-2b alonepatitis C. H
patients with
Is an “à lae first line tre
Internationals C virus inf
fa-2b plus rof chronic h
ha 2a and rf treatment d
n combinatioents: final re
n with pegintype 1 HCV pase 3 ILLUM
d with pegint(HCV) geno
Hepatol 201
epatitis C. 2report.pdf.
e 49 of 61
erferon-pective
py with ed with irrhosis
on liver atology
e or in epatitis
chronic
a carte” eatment
l Study fection.
ribavirin epatitis
ribavirin duration
on with sults of
terferon patients MINATE
terferon otype 1:
14; doi:
014: 1-
Versio
[4
[4
[4
[5
[5
[5
[5
[5
[5
[5
[5
[5
[5
[6
No use or on 3.0 (22 Apr 2
47] Jacobribavir(QUE2014;
48] Mann2b pluinfectiLance
49] Fornsto higtherap
50] Reddyevaluawith treatmAustra
51] Full http://wFebru
52] Lawitzhepat
53] Lalezaweeks2013;
54] Osinugenottrial. J
55] MenoproteavoluntHawa
56] Feld Jand d
57] Zeuzeombita
58] AndredasabribavirGastro
59] Ferenwithou
60] Poordfor he
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
bson IM, Dorerin in treatmeST-1): a ph doi: 10.1016s M, Marcellus ribavirin inion (QUESTet 2014; doi: s X, Lawitz Egh rates of Spy: a phase 3y KR, Zeuzeate the efficapegylated in
ment-experienalia. Availabl
prescrwww.olysio.c
uary 09, 2014z E, Mangiaitis C infectioari L, Nelsons in treatmen 58 (Suppl 1)
usi A, Meissype 1 in patie
JAMA 2013; 3n RM, Klein ase inhibitorteers with a
aii, USA. AvaiJJ, Kowdley asabuvir with
em S, Jacobasvir and das
eone P, Colobuvir achieverin in treatoenterology
nci P, Bernstut ribavirin fodad F, Hezodepatitis C with
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
e G, Foster Gent-naive pathase 3, rand6/S0140-673in P, Poordan treatment-n
T-2): a rando10.1016/S01
E, Zeuzem S,SVR in patie3 trial. Gastroem S, Zoulimacy, safety anterferon annced patiente at http://wwribing com/shared/p4. a A, Wyles on. NEJM 20 D, Hyland R
nt-naive patie): S346.
sner EG, Leents with unf310: 804-11.CE, Lawal A
r ABT-450 and without ilable at http:KV, Coakley
h ribavirin. Nbson IM, Basabuvir with ombo MG, Ees 97% andtment-experi2014; doi: 10ein D, Lalez
or HCV. NEJMde C, Trinh Rh cirrhosis. N
vir and dasab
nfidential Informermitted witho
06.2015
G et al. Simetients with chdomised, do6(14)60494-
ad F, et al. Sinaive patientomised, dou140-6736(14), et al. Sime
ents with HCoenterology.
m F, et al. A Pand tolerabilitnd ribavirin ts: the ATTAww.natap.org
informationproduct/olysi
D, et al. S13; 368: 187
R, et al. Onceents with HCV
ee YJ, et alfavorable trea. AA, et al. Phfollowing sritonavir. Ab://www.natapy E, et al. TrEJM 2014; 3aykal T, et ribavirin. NEEnejosa JV, d 100% susenced patie
0.1053/j.gastzari J, et al. AM 2014; 370:
R, et al. ABT-4EJM 2014; 3
buvir
mation ut prior written
eprevir with phronic hepat
ouble-blind, p3 (Epub ahemeprevir withts with chronble-blind, pla)60538-9 (Epprevir with P
CV genotype 2014; 146: 1Phase III ranty of simeprein chronic
AIN study. Ag/2014/APASn Olyo/prescribing
Sofosbuvir fo78-87. e daily sofosbV infection: t
l. Sofosbuviatment chara
harmacokinesingle ascenbstract of Hp.org/2009/hereatment of
370: 1594-60al. Retreatm
JM 2014; 37et al. ABT-
stained viroloents with tro.2014.04.0ABT-450/r-om: 1983-92. 450/r-ombita
370: 1973-82
n authorization
pegylated intitis C virus gplacebo-contad of print). h pegylated nic hepatitis acebo-contropub ahead ofPeginterferon
1 who relap669-79.
ndomised, doevir vs telaprhepatitis C
Abstract APASL/APASL_20ysio. Ag-information
or previously
buvir plus ribthe QUANTU
r and ribaviacteristics: a
etics and tolending dosesepDART 20epDART/hepHCV with AB3. ment of HC
70: 1604-14. -450, ritonavogic responsHCV genot
045 (Epub ahmbitasvir and
asvir and das2.
from AbbVie Page
erferon alfa 2genotype 1 introlled trial.
interferon alfC virus genoolled phase f print). and ribavirinpsed after p
ouble-blind srevir in comb
virus genoASL 2014 Br0.htm. Available
n.pdf; ac
y untreated
bavirin for 12 UM study. J H
irin for heparandomized
erability of ths in healthy009, Kohala pDART_03.htBT-450/r om
CV with ABT
vir, ombitasvse with or type 1b infhead of print)d dasabuvir
sabuvir with r
e 50 of 61
2a plus nfection Lancet
fa 2a or otype 1 3 trial.
n leads revious
study to bination otype 1 risbane,
at ccessed
chronic
and 24 Hepatol
atitis C clinical
he HCV y adult
Coast, tm. bitasvir
T-450/r-
vir, and without fection. ). with or
ribavirin
Versio
[6
[6
[6
[6[6
[6
[6
[6
No use or on 3.0 (22 Apr 2
61] Hezodinterfewith H
62] HezodtreatmGastro
63] Colomtelapr2014;
64] Marle65] Singa
Trans66] Marce
rapid results
67] ThomkineticGastro
68] Internhttp://wrole-
Paritaprevir/P15-743 Pro
disclose outsid015) – country v
de C, Marceeron-free regHCV genotypde C, Fonta
ment-experienoenterology
mbo M, Fernárevir: the ear 63: 1150-8. y J. Efficacy,
al AG, Higgins Gastroenterellin P, Cheinvirologic ress from randopson AJ, Mcs and is thoenterology ational Cwww.icmje.o
of-authors-an
/r – ombitasvotocol
Conde AbbVie is pv 1.0 dated 26.0
ellin P, Polgimens of ABe 4 infectionine H, Dorivnced patien2014; 147: 1ández I, Abdrly access p